Veracyte (VCYT +3.8%) inks an agreement with
Yale University for exclusive rights to a 52-gene molecular test for
predicting disease progression idiopathic (cause unknown) pulmonary
fibrosis (IPF) patients.
Dr. Naftali Kaminski, chief of the Section of
Pulmonary, Critical Care and Sleep Medicine in the Department of
Medicine at Yale University’s School of Medicine developed the test with
collaborators.
The company plans to offer the non-invasive blood
test as a complement to its Envisia Genomic Classifier as a
comprehensive aid in the diagnosis and treatment of IPF.
Financial terms are not disclosed.
https://seekingalpha.com/news/3563743-veracyte-in-licenses-pulmonary-fibrosis-test-shares-ahead-4
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.